Cancer – ANBL1232: Utilizing Response - and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma - a Groupwide Historically Controlled Phase 3 Study
Condition or Therapy:
Cancer and Blood Disorders
Study Number: ANBL1232
What is the goal of this study?
The goal of this study is to use response- and biology-based, risk-guided therapy in treating patients with non-high-risk neuroblastoma instead of using standard treatment.
Who can join the study?
This study may be a good fit for children and young adults who:
- Are less than 1 years old at diagnosis with INRG Stage L1; or
- Are less than 18 months old at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma
Enrollment on ANBL00B1 or APEC14B1 is required for all newly diagnosed patients.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.